Acute ischaemic stroke is characterised by reductions in local cerebral blood flow (CBF) and activation of circulating platelets and leucocytes. Nitric oxide is a vasodilator and can inhibit these circulating cells. The aim of this study was to assess the effect of nitric oxide on platelet function and regional CBF in patients with acute ischaemic stroke. Sodium nitroprusside (SNP), a spontaneous nitric oxide donor, was administered at a dose which caused a 10 mm Hg fall in mean arterial blood pressure (MABP) in a pathophysiological study to 22 patients with acute ischaemic stroke and 12 matched control subjects. Platelet function (whole blood aggregation and flow cytometry) was assessed before and during SNP administration. Changes in regional CBF were measured using single photon emission computerised tomography (SPECT) scanning. SNP significantly reduced platelet aggregation in both the patient and control subject groups. Equally, the expression of platelet adhesion molecules P-selectin (CD62) and glycoprotein (GP) GP IIIa (CD61) were significantly reduced in both groups. GP Ia (CDw49b) expression was significantly attenuated in the patient but not in the control group. Four patients underwent SPECT scanning and improvements in local CBF corresponding to the penumbral area of the clinical stroke site were seen in 3 of these patients. A total of 24 regions of asymmetrical perfusion were examined, pre-SNP (median (SQR)), 0.68 (0.14) vs. peri-SNP 0.78 (0.17), 2p = 0.065. SNP, given at a dose which reduced MABP by 10 mm Hg, significantly inhibited platelet aggregation and adhesion molecule expression. Improved regional CBF was seen in some patients. SNP is a candidate therapeutic agent for patients with acute ischaemic stroke and warrants further study.

Keywords:
Ischaemic stroke, Nitric oxide, Platelet aggregation, Platelet activation, Single photon emission tomography
1.
Ross R: The pathogenesis of atherosclerosis: A perspective for the 1990s. Nature 1993;362:801–809.
2.
Trowbridge EA, Slater DN, Kishk YT, Woodcock BW, Martin JF: Platelet production in myocardial infarction and sudden cardiac death. Thromb Hameost 1984;52:167–171.
3.
Moncada S, Palmer RMJ, Higgs EA: Nitric oxide: Physiology, pathophysiology and pharmacology. Pharmacol Rev 1991;43:109–142.
4.
Huang PL, Huang Z, Mashimo H, Bloch KD, Moskowitz MA, Bevan JA, Fishman MC: Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239–242.
5.
Rapoport RM, Murad F: Agonist induced endothelium-dependent relaxation in rat thoracic aorta may be mediated through cyclic GMP. Circ Res 1983;52:352–357.
6.
Radomski MW, Palmer RMJ, Moncada S: Comparative pharmacology of endothelium-derived relaxing factor, nitric oxide and prostacyclin in platelets. Br J Pharmacol 1987;92:181–187.
7.
Radomski MW, Palmer RMJ, Moncada S: Endogenous nitric oxide inhibits human platelet adhesion to vascular endothelium. Lancet 1987;ii:1057–1058.
8.
Gerzer R, Karrenbrock B, Siess W, Heim J-M: Direct comparison of the effects of nitroprusside, SIN-1, and various nitrates on platelet aggregation and soluble guanylate cyclase activity. Thromb Res 1988;52:11–21.
9.
Bath PMW, Hassall DG, Gladwin A-M, Palmer RMJ, Martin JF: Nitric oxide and prostacyclin. Divergence of inhibitory effects on monocyte chemotaxis and adhesion to endothelium in vitro. Arterioscler Thromb 1991;11:254–260.
10.
Bath PMW: The effect of nitric oxide donating vasodilators on monocyte chemotaxis and intracellular cGMP concentrations in vitro. Eur J Clin Pharmacol 1993;45:53–58.
11.
Forslund T, Sundqvist T: Nitric oxide reduces hydrogen peroxide production from human polymorphonuclear neutrophils. Eur J Clin Invest 1995;25:9–14.
12.
Mariotto S, Cuzzolin L, Adami A, Del Soldato P, Suzuki H, Benoni G: Inhibition of sodium nitroprusside of the expression of inducible nitric oxide synthase in rat neutrophils. Br J Pharmacol 1995;114:1105–1106.
13.
Bath PMW: Treating acute ischaemic stroke. Br Med J 1995;311:139–140.
14.
International Stroke Trial Collaborative Group: The International Stroke Trial (IST); a randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997;349:1569–1581.
15.
CAST (Chinese Acute Stroke Trial) Collaborative Group: CAST: Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997;349:1641–1649.
16.
East SJ, Batchelor AM, Garthwaite J: Selective blockade of N-methyl-D-aspartate receptor function by the nitric oxide donor, nitroprusside. Eur J Pharmacol 1991;209:119–121.
17.
Manzoni O, Prezeau L, Deshager S, Sahuquet A, Sladeczek F, Bockaert J, Fagni L: Sodium nitroprusside blocks NMDA receptors via formation of ferrocyanide ions. NeuroReport 1992;3:77–80.
18.
Moncada S, Higgs A: The L-arginine-nitric oxide pathway. N Engl J Med 1993;329:2002–2012.
19.
Bath PMW, Butterworth RJ, Soo J, Kerr JE: The King’s College Hospital Acute Stroke Unit. J R Coll Phys (Lond) 1996;30:13–17.
20.
Bamford J, Sandercock P, Dennis M, Burn J, Warlow C: Classification and natural history of clinically identifiable subtypes of cerebral infarction. Lancet 1991;337:1521–1526.
21.
Bath FJ, Bath PMW: What is the correct management of blood pressure in acute stroke? The Blood Pressure in Acute Stroke Collaboration. Cerebrovasc Dis 1997;7:205–213.
22.
Russell-Smith NC, Flower RJ, Cardinal DC: Measuring platelet and leucocyte aggregation/adhesion responses in very small volumes of whole blood. J Pharm Meth 1981;6:315–333.
23.
Cardinal DC, Flower RJ: The electronic aggregometer: A novel device for assessing platelet behaviour in blood. J Pharm Meth 1980;3:135–158.
24.
Shattil SJ, Cunningham M, Hoxie JA: Detection of activated platelets in whole blood using activation dependent monoclonal antibodies and flow cytometry. Blood 1987;70:307–315.
25.
Holmes RA, Chaplin SB, Royston KG, Hoffman TJ, Volkert WA, Nowotnik DP, Canning LR, Cumming SA, Harrison RC, Higley B: Cerebral uptake and retention of 99mTc-HMPAO. Nucl Med Commun 1985;6:443–447.
26.
Podreka I, Suess E, Goldenberg G, Steiner M, Brücke T, Müller C, Lang W, Neirinckx RD, Deecke L: Initial experiences with technetium-99m HMPAO brain SPECT. J Nucl Med 1987;28:1657–1666.
27.
Mountz JM, Deutsch G, Khan SH: Regional cerebral blood flow changes in stroke imaged by Tc-99m HMPAO SPECT with corresponding anatomic image comparison. Clin Nucl Med 1993;18:1067–1082.
28.
Talairach G, Tournoux P: Co-Planar Stereotaxic Atlas of the Human Brain. New York, Thieme, 1988.
29.
Siegal S, Castellan NJ: Nonparameteric Statistics for the Behavioural Sciences, ed 2. London, McGraw-Hill, 1988.
30.
Nurden AT: Human platelet membrane glycoproteins; in Bloom AL, Forbes CD, Thomas DP, Tuddenham EGD (eds): Haemostasis and Thrombosis, ed 3. Edinburgh, Churchill-Livingstone, 1994, pp 115–165.
31.
Waltz AG: Effect of blood pressure on blood flow in ischaemic and in nonischaemic cerebral cortex: The phenomena of autoregulation and luxury perfusion. Neurology 1968;18:613–621.
32.
Fieschi C, Agnoli A, Battistini N, Bozzao L, Prencipe M: Derangement of regional cerebral blood flow and of its regulatory mechanisms in acute cerebrovascular lesions. Neurology 1968;18:1166–1179.
33.
Dahl A, Russell D, Nyberg-Hansen R, Rootwelt K: Effect of nitroglycerin on cerebral circulation measured by transcranial doppler and SPECT. Stroke 1989;20:1733–1736.
34.
Joshi S, Young WL, Pile-Spellman J, Fogarty-Mack P, Sciacca RR, Hacein-Bey L, Duong H, Vulliemoz Y, Ostapkovich N, Jackson T: Intra-arterial nitrovasodilators do not increase cerebral blood flow in angiographically normal territories of arteriovenous malformation patients. Stroke 1997;28:1115–1122.
35.
Reutens DC, McHugh MD, Toussaint P-J, Evans AC, Gjedde A, Meyer E, Stewart DJ: L-Arginine infusion increases basal but not activated cerebral blood flow in humans. J Cereb Blood Flow Metab 1997;17:309–315.
36.
Zhang F, Iadecola C: Nitroprusside improves blood flow and reduces brain damage after focal ischaemia. NeuroReport 1993;4:559–562.
37.
Zhang F, White JG, Iadecola C: Nitric oxide donors increase blood flow and reduce brain damage in focal ischaemia: Evidence that nitric oxide is beneficial in the early stages of cerebral ischaemia. J Cereb Blood Flow Metab 1994;14:217–226.
38.
Morikawa E, Huang Z, Moskowitz MA: L-Arginine decreases infarct size caused by middle cerebral artery occlusion in SHR. Am J Physiol 1992;263:H1632–H1635.
39.
Morikawa E, Moskowitz MA, Huang Z, Yoshida T, Irikura K, Dalkara T: L-Arginine infusion promotes nitric oxide dependent vasodilation, increases regional cerebral blood flow, and reduces infarction volume in the rat. Stroke 1994;25:429–435.
40.
Huang Z, Huang PL, Fishman MC, Moskowitz MA: Focal cerebral ischaemia in mice deficient in either endothelial (eNOS) or neuronal nitric oxide (nNOS) synthase (abstract). Stroke 1996;27:173.
41.
Huang Z, Huang PL, Panahian N, Dalkara T, Fishman MC, Moskowitz MA: Effects of cerebral ischaemia in mice deficient in neuronal nitric oxide synthase. Science 1994;265:1883–1885.
42.
del Zoppo GJ: Why do all drugs work in animals but none in stroke patients? 1. Drugs promoting cerebral blood flow. J Intern Med 1995;237:79–88.
43.
Grotta J: Why do all drugs work in animals but none in stroke patients? 2. Neuroprotective therapy. J Intern Med 1995;237:89–94.
44.
Butterworth RJ, Bath PMW: The effect of nitric oxide on platelet function in acute ischaemic stroke (abstract). Cerebrovasc Dis 1996;6(suppl 2):6.
1998
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.